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Abstract 25 
Flavobacterium psychrophilum is the causative agent of Rainbow Trout Fry Syndrome which 26 
has had a major impact on global salmonid aquaculture. Recent outbreaks in Atlantic salmon 27 
in Scotland and Chile have added to the need for a vaccine to protect both salmon and trout.  28 
At present no licensed vaccines are available in Europe, leaving antibiotics as the only course 29 
of action to contain disease outbreaks. Outbreaks generally occur in fry at temperatures 30 
between 10-15 °C. Recently outbreaks in larger fish have given added impetus to the 31 
development of a vaccine which can provide long term protection from this highly 32 
heterogeneous pathogen. Most fish injectable vaccines are formulated with oil emulsion 33 
adjuvants to induce strong and long lasting immunity, but which are known to cause side 34 
effects. Alternative adjuvants are currently sought to minimise these adverse effects. 35 
The current study was performed to assess the efficacy of a polyvalent, whole cell vaccine 36 
containing formalin-inactivated F. psychrophilum to induce protective immunity in Atlantic 37 
salmon. The vaccine was formulated with an adjuvant containing squalene and aluminium 38 
hydroxide, and was compared to a vaccine formulated with a traditional oil adjuvant, 39 
Montanide ISA 760VG, and a non-adjuvanted vaccine. Duplicate groups of salmon (23.5 ± 40 
6.8 g) were vaccinated with each of the vaccine formulations or phosphate buffered saline by 41 
intraperitoneal injection. Fish were challenged by intramuscular injection with F. 42 
psychrophilum six weeks post-vaccination to test the efficacy of the vaccines. Cumulative 43 
mortality reached 70% in the control salmon, while the groups of salmon that received 44 
vaccine had significantly lower mortality than the controls (p = 0.0001), with no significant 45 
difference in survival between vaccinated groups. The squalene/alum adjuvant was safe, more 46 
readily metabolised by the fish and induced less histopathological changes than the traditional 47 
oil adjuvant. 48 
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 50 
1 Introduction 51 
Rainbow trout fry syndrome (RTFS), caused by Flavobacterium psychrophilum, is one of the 52 
most significant disease problems facing the salmonid aquaculture industry worldwide [1]. 53 
Rainbow trout (Oncorhynchus mykiss) are the species most affected although there are 54 
increasing problems in Atlantic salmon (Salmo salar) hatcheries in Scotland and Chile. 55 
Disease episodes tend to occur between 10-15 ºC, with necrotic lesions often seen on the skin 56 
surrounding the dorsal fin and tail, while in very small fish no clinical signs are apparent and 57 
death occurs due to septicaemia. F. psychrophilum is a highly heterogeneous pathogen, which 58 
makes development of cross-protective vaccines to control this devastating disease 59 
problematic [2]. Antibiotic treatment is relied on to treat outbreaks, which has led to increased 60 
levels of antibiotic resistance in F. psychrophilum isolates [3-5], highlighting the urgent need 61 
for prophylactic treatments for RTFS.  62 
The majority of inactivated whole cell or sub-unit vaccines available to the aquaculture 63 
industry are formulated in oil emulsions [6]. Adjuvanted vaccines are injected 64 
intraperitoneally, and provide protection via a prolonged release of antigen from the oil 65 
component stimulating primarily local inflammatory reactions followed by a systemic 66 
immune response [7]. While oil-based adjuvants have provided increased efficacy of vaccines 67 
for aquaculture, problems with side-effects at injection sites have resulted in the down grading 68 
of fish at harvest due to adhesions between the body wall and abdominal organs and spinal 69 
deformities [8-10] . Therefore, there is a need to develop adjuvants for use in injectable 70 
vaccines for salmonids, which balance the efficacy-safety profile. A previous study using an 71 
adjuvant containing squalene and aluminium hydroxide to formulate a vaccine for treatment 72 
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of viral haemorrhagic septicaemia (VHS) in Olive flounder (Paralichthys olivaceus), resulted 73 
in an efficacious vaccine inducing long term protection without injection site reactions, 74 
adhesions or pigmentation [11]. 75 
The current study was performed to assess the efficacy of a polyvalent, whole cell 76 
vaccine containing formalin-inactivated F. psychrophilum, with and without different 77 
adjuvants, to induce protective immunity in Atlantic salmon fry. A mixture of 78 
squalene/aluminium hydroxide was tested as an alternative adjuvant to the traditional oil 79 
adjuvant (Montanide) and compared to protection achieved by vaccine without adjuvant. 80 
Immune responses were investigated post-vaccination/pre-challenge by ELISA and western 81 
blot in addition to immune gene expression and histological investigation of the injection site.  82 
 83 
2 Materials and Methods 84 
2.1  Atlantic Salmon Fry 85 
Atlantic salmon eggs were supplied by AquaGen (Norway) and transported on ice to the 86 
aquarium at the Institute of Aquaculture, Stirling. On arrival eggs were subjected to an 87 
iodophor surface disinfectant treatment according to the manufacturer’s instructions 88 
(Buffodine, Evans Vanodine, UK). Five replicates of 10 eggs were removed and confirmed to 89 
be F. psychrophilum free using a nested PCR for the 16S rRNA gene with modifications 90 
[12,13]. The eggs were maintained in flow-through de-chlorinated tap water at 10 ºC until 91 
hatch, and thereafter maintained in a 100 L flow-through tank (5 L min-1). The fry were fed to 92 
satiation daily (Inicio feed, 1.1 mm, BioMar, UK). All experimental procedures with live fish 93 
were carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986 and 94 
associated guidelines, EU Directive 2010/63/EU for animal experiments and were approved 95 
by the Ethics Committee of the Institute of Aquaculture, University of Stirling, UK.  96 
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 97 
2.2 Preparation of formalin inactivated bacteria 98 
Two isolates of F. psychrophilum recovered from trout and one recovered from salmon in the 99 
UK in 2013 were used to make the whole cell vaccine (Table 1) as described in [14].  100 
 101 
Table 1.  Details of the isolates of F. psychrophilum included in the experimental vaccine: species, 102 
geographical source and serotype. 103 
ISOLATE FISH SPECIES SOURCE SEROTYPE [15] 
AVU-1T/13 Rainbow Trout England Th 
AVU-2T/13 Rainbow Trout Scotland Fd 
AVU-3S/13 Atlantic salmon Scotland FpT 
 104 
2.3 Preparation of Vaccine formulations and Vaccination 105 
The formalin-inactivated vaccine (formalin killed cells: FKC) was emulsified with 106 
squalene/alum adjuvant [(5 (v/v) % squalene (Sigma, Australia), 20 (v/v) % glycerol 107 
(Ameresco, USA), 0.5 (v/v) % Tween 80 (Sigma-Aldrich, USA) and 0.5 (w/v) % aluminium 108 
hydroxide (Sigma, USA)] or with Montanide ISA760VG (Seppic, France) (Montanide 70: 109 
FKC 30). The vaccine formulations were stored at 4 ºC and the stability of the emulsion was 110 
examined macro and microscopically following a period of 7 days. 111 
Fish (23.5 ± 6.8 g) were randomly separated into 100 L flow-through tanks with 112 
aeration at 15 ºC. The experimental design of the vaccination trial is summarised in Table 2. 113 
Fish were anaesthetised with benzocaine (Sigma, 0.004%) and given one of the vaccine 114 
formulations by intra-peritoneal injection (50 µl per fish). Control groups were injected i.p. 115 
with 50 µl of sterile PBS. Fish were euthanized by an over-dose of benzocaine and sampling 116 
carried out at various time points (Table 2). Tissues (spleen, liver, kidney, intestine and heart) 117 
from three fish per replicate were collected and immediately fixed in formaldehyde in PBS 118 
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(100 mL 35% formaldehyde and 900 mL DW) for histology. Head-kidney from three fish per 119 
duplicate group (n=6) was placed immediately in RNA-later (Sigma) and stored at 4 ºC 120 
overnight. RNA-later was removed and tissues stored at -70 ºC until RNA extraction. Blood 121 
was sampled from the caudal vein using a 23 G needle and syringe from three fish per 122 
duplicate group (n=6) stored overnight at 4 ºC, centrifuged  at 3000 x g 5 min for collection of 123 
serum which was stored at -20 ºC until analysis.  124 
 125 
Table 2. Experimental design of vaccination trial and sampling. 126 
Groups No. Fish/ 
replicate 
Innoculum        
 (50 µl i.p.) 
Challenge 
(no.CFU/fish) 
Sampling point 
 (samples taken) 
Control 
(unvaccinated) 
 
Vaccine (FKC) 
 
Vaccine + 
squalene/alum  
 
Vaccine + Montanide  
 
21 x 2              
 
 
21 x 2 
 
 
21 x 2 
 
21 x 2 
 PBS 
 
 
FKC 
 
 FKC: 
Squalene/alum 
 
 FKC: Montanide 
Homologous 
(4.0 x 107) 
Day 2 pv 
(tissues qPCR) 
 
6 wpv 
(Blood, tissues) 
 127 
2.4 Experimental infection of vaccinated fish 128 
Vaccinated and control fish were experimentally infected with a homologous isolate of F. 129 
psychrophilum (AVU-3S/13) at 4.0 x 107 CFU/fish six weeks post-vaccination (wpv) by 130 
intramuscular injection. The fish were maintained as above and monitored for 21 days post 131 
infection (dpi). Moribund fish or mortalities were removed and sampled by streaking head 132 
kidney, spleen and any lesions on Modified Veggietone (MV) medium [veggitones GMO-free 133 
soya peptone (Oxoid, UK), 5 g L-1; yeast extract (Oxoid, UK), 0.5 g L-1; magnesium sulphate 134 
heptahydrate (Fisher chemicals, UK), 0.5 g L-1; anhydrous calcium chloride (BHD), 0.2 g L-1; 135 
dextrose (Oxoid, UK), 2 g L-1; agar (solid medium; Oxoid, UK), 15 g L-1; pH 7.3]  to confirm 136 
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specific mortality. A sub-sample of colonies recovered was examined for the presence of F. 137 
psychrophilum using a nested PCR method [12,13]. 138 
 139 
2.5 ELISA for detection of specific IgM in serum 140 
Enzyme-linked immunosorbent assay (ELISA) was used to assess specific IgM titre to F. 141 
psychrophilum in serum according to [16] with some modifications. F. psychrophilum 142 
vaccine isolates and a heterologous isolate were used to coat the plates at 1 x 108/mL in PBS 143 
and incubated overnight at 4 °C. The dilution of fish serum used was optimised by first 144 
titrating sera from each group (1:32 to 1:1024). Fish serum samples at the optimised dilution 145 
of 1:64 in PBS were added to the wells (100 μl/well) in duplicate and incubated overnight at 4 146 
°C. Specific IgM was detected using anti-trout IgM monoclonal antibody (Aquatic 147 
Diagnostics Ltd., 1/33 in PBS, 1h) followed by incubation with anti-mouse-HRP (1/4000, 148 
Sigma, 1h). The absorbance was read on a BioTek HT Synergy spectrophotometer at 450 nm. 149 
 150 
2.6 SDS-PAGE and Western blotting 151 
2.6.1 Sodium dodecyl sulphate polyacramide gel electrophoresis (SDS-PAGE)  152 
Suspensions of the three vaccine isolates and a heterologous isolate of F. psychrophilum were 153 
aliquoted into 1.5 ml microcentrifuge tubes (1 mL of 2 x 108 cfu/mL), and centrifuged for 15 154 
min at 3000 × g. Bacterial pellets were resuspended in 100 µl of DW and 30 µl of 5 X sample 155 
buffer (250mM Tris-HCl, 30% glycerol, 10% SDS, 0.5M dithiothreitol, 0.2% bromophenol 156 
blue) and boiled for 15 min. Finally, the samples were centrifuged at 10,000 × g for 10 min 157 
prior to analysis of the supernatants. A preparation of broad-range molecular weight markers 158 
(5 µl) (Bio-Rad) were added to the first well of a 12% polyacrylamide gel (Bio-Rad) and 15 159 
µl of each sample were added to the remaining wells. The gel was run at 130 V for 160 
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approximately 90 min. The gel was stained in 50 mL of Coomassie (QC Colloidal Coomassie 161 
Stain, Bio-Rad) according to the manufacturer’s instructions. 162 
 163 
2.6.2 Western blot analysis  164 
Bacterial components separated by SDS-PAGE as described above were transferred onto 165 
nitrocellulose membranes by semi-dry transfer (Pierce™ Power Blotter, ThermoFischer 166 
Scientific) applying 25 V (1.3A) for 7 min. The nitrocellulose membranes were then 167 
incubated overnight at 4 °C in 5 % (w/v) casein in distilled water (DW). After washing 3 168 
times with Tris buffered saline with Tween (TBS: 10 mM Tris base, 0.5 M NaCl pH 7.5 with 169 
0.1% [v/v] Tween 20) for 5 min at each wash, the membranes were incubated for 3 h at 22 °C 170 
with a 1/20 dilution of fish serum in TBS (serum was a pool from 2 fish from each treatment 171 
group, with a titre of 1/512, taken six wpv as described in Section 2.6). The membranes were 172 
washed as previously described and incubated for 1 h at 22 °C with a 1/20 dilution of anti-173 
trout IgM monoclonal antibody in TBS (ADL). The membranes were again washed and 174 
incubated for 1 h at 22 °C with a 1/200 dilution of anti-mouse horse radish peroxidase 175 
(Sigma) in TBS. After washing, bands were visualised by adding chromogen and substrate 176 
(ImmPACT™ DAB Peroxidase substrate kit). The reaction was stopped by soaking the 177 
membranes in DW for 5 min. 178 
 179 
2.7 Histology 180 
Formalin fixed tissues were embedded in paraffin and sectioned using a Microtome (Shandon 181 
Finesse). Tissue sections were de-waxed and dehydrated in xylene (2 x 3 min), 100% ethanol 182 
(2 min), methylated spirit (1.5 min) and stained with haematoxylin and eosin. Slides were 183 
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examined using an Olympus BX40 microscope for signs of inflammation or adverse reactions 184 
to the vaccine/adjuvants and scored for inflammation and lipid droplets at the injection site. 185 
 186 
2.8 Isolation of total RNA and cDNA synthesis 187 
RNA was extracted from 30 - 40 mg of each head-kidney sample using TRI Reagent (Applied 188 
Biosystems) following the manufacturer’s protocol. The resultant RNA pellet was re-189 
suspended in 30 µL of nuclease-free water. Following spectrophotometric quantification 190 
(Nanodrop ND-1000, Thermo Fisher, Leicestershire, UK) and quality checking by gel 191 
electrophoresis (1% agarose gel stained with ethidium bromide), samples were stored at -70 192 
ºC until required. RNA was reverse transcribed to construct cDNA using a high-capacity 193 
cDNA Reverse Transcription kit (Applied Biosystems, USA) according to the manufacturer’s 194 
instructions. Briefly, 10 μl of RNA was added to 10 μl of 2X RT master mix (10X RT buffer, 195 
25X dNTP Mix 100 mM, 10XRT Random Primers and oligo-dT mix, Reverse Transcriptase, 196 
RNase Inhibitor, nuclease-free water). The thermal cycle conditions consisted of 25 °C for 10 197 
min, 37 °C for 120 min and 85 °C for 5 min. The cDNA was aliquoted and stored at -20 °C 198 
prior to use. 199 
 200 
2.9 Quantitative Real Time PCR (qRT-PCR) 201 
Head-kidney samples were analysed by qRT-PCR for the expression of cytokines (IL-1β, IL-202 
8, IL-10, IFN-γ) and immune genes (CD4, CD8). Real time PCR was performed on first 203 
strand cDNA using the Eppendorf® RealPlex2 Mastercycler gradient S instrument with 204 
SYBR® Green I (Thermo Scientific) master mix and primers as shown in Table 3.  205 
 206 
Table 3. Primers used for qPCR including product size and sequences. 207 
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 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
Briefly the 20 μl reaction consisted of 5 μl of cDNA and 15 μl of master mix prepared using 1 216 
μl of the forward and reverse primers (0.3 µM), 10 μl SYBR® Green I and 3 μl of nuclease 217 
free water. The cycling conditions consisted of 95°C initial denaturing for 15 s, followed by 218 
40 cycles of 15 s denaturing at 95 °C, 30 s annealing at 58 °C and 30 s extension at 72 °C. 219 
RT-minus and non-template controls were included on every plate. Melting curve analysis 220 
was performed from 60 °C to 95 °C in 0.1 °C/s increments to assess the specificity of the RT-221 
PCR products. Serial 10-fold dilutions of the cDNA were prepared in nuclease free water 222 
starting and the Ct values were used to generate a standard curve plot of cycle number versus 223 
log concentration in the realplex software V2.2 (Eppendorf).  The quality of the standard 224 
curve was judged by the slope of the curve and the correlation coefficient (r). The slope of the 225 
line was used to estimate the estimate the efficiency of the target amplification using the 226 
equation E= (10-1/slope)-1. Elongation factor-α and β-actin were used as reference genes to 227 
correlate for potentially different loading amounts of RNA and for variation in cDNA 228 
synthesis efficiencies [22].  The threshold cycle (Ct) was determined at the linear slope in a 229 
log fluorescence/Ct plot. The expression results were analysed using the 2 -ΔΔ Ct method [23]. 230 
Gene Primers Product 
size 
Reference Efficiency 
(E) 
IL-1β F: GCTGGAGAGTGCTGTGGAAGA 
R: TGCTTCCCTCCTGCTCGTAG 
73 [17] 0.90 
IL-10 F: CTGTTGGACGAAGGCATTCTAC 
R: GTGGTTGTTCTGCGTTCTGTTG 
129 [18] 0.95 
IFNγ F: CTAAAGAAGGACAACCGCAG 
R: CACCGTTAGAGGGAGAAATG 
159  [19] 0.96 
CD8α F: AATCAATGGTAACGCGCTTG 
R: TGGCTGTGGTCATTGGTGTA 
101 [20] 0.97 
CD4 F: GAGTACACCTGCGCTGTGGAAT 
R:GGTTGACCTCCTGACCTACAAAGG 
121 [19] 0.85 
IL-8 F: ATTGAGACGGAAAGCAGACG 
R: CGCTGACATCCAGACAAATCT 
136 [21] 0.85 
Elongation 
factor 1α 
F:CGGCAAGTCCACCACCAC 
R:GTAGTACCTGCCAGTCTCAAAC 
205 [21] 0.94 
Β-actin F: ACTGGGACGACATGGAGAAG 
R: GGGGTGTTGAAGGTCTCAAA 
157 [21] 0.91 
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The gene expression data were normalised to the reference genes and expressed as a 231 
comparison of vaccinated fish compared to control fish using REST 2009™ software [24]. 232 
 233 
2.10 Statistical Analysis 234 
Minitab software version 16 (Minitab Inc., Pennsylvania) was used to perform basic 235 
descriptive statistics and SPSS™ for survival analysis. Relative percentage survival (RPS) 236 
was calculated at the time point corresponding to when mortality had ceased in the control 237 
group (3 consecutive days of no mortality). Kaplan-Meier survival curves were generated and 238 
the log-rank test was used to compare the survival curves for the vaccinated fish and 239 
unvaccinated fish [25,26]. The relative percent survival (RPS) of this trial was calculated 240 
using the following equation [27]: 241 
  242 
RPS = [1 – 
average % mortality of vaccinated fish 
] x 100 
average % mortality of unvaccinated fish 
 243 
Specific antibody levels were analysed by one-way ANOVA followed by Welch’s test.  244 
 245 
3. Results 246 
3.1 Vaccine Efficacy 247 
All vaccinated groups showed significant protection to disease challenge compared with the 248 
controls when average percentage survival was calculated (p = 0.0001, Fig 1). Pairwise 249 
comparisons of individual tanks are given in supplementary table 1. Average cumulative 250 
mortality reached 70% in the control salmon. The vaccine formulation of formalin-killed cells 251 
(FKC) combined with Montanide ISA 760VG gave the highest protection (RPS of 95.2%), 252 
vaccine (FKC) without adjuvant and vaccine formulated with squalene/alum adjuvant also 253 
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induced good protection with RPS values of 85.71% and 75.17% respectively. No significant 254 
difference in survival was found between vaccinated groups. DNA samples extracted from 255 
selected bacterial colonies recovered from fish that had died post-challenge were positive for 256 
F. psychrophilum by nested PCR.  257 
 258 
Figure 1. Cumulative percentage survival of salmon vaccinated by intraperitoneal injection with Flavobacterium 259 
psychrophilum formalin killed bacterin with and without adjuvant and challenged 630 degree days post-260 
vaccination by intramuscular injection with one of F. psychrophilum vaccine strains (AVU-3S/13). Survival of 261 
each duplicate tank is shown. Average Relative percent survival (RPS): FKC: formalin-killed cells (85.71%); 262 
FKC & Squalene: formalin-killed cells emulsified with squalene and alum adjuvant (RPS 75.17%); FKC & 263 
Montanide: formalin-killed cells emulsified with Montanide ISA 760VG (RPS 95.24%). Controls were given 264 
sterile phosphate buffered saline by intraperitoneal injection. 265 
 266 
3.2 Nested PCR for detection of F. psychrophilum 267 
The eggs were free of F. psychrophilum (Fig. S1a) and F. psychrophilum was detected in 268 
moribund and dead fish sampled during the challenge (Fig. S1b).   269 
  270 
3.3 Specific antibody response  271 
Antibody levels (IgM) were measured at a 1:64 dilution as this gave the best resolution 272 
between groups.  Antibody levels of vaccinated fish screened against a F. psychrophilum 273 
vaccine isolate (AVU-3S/13, serotype FpT) 6 wpv were significantly elevated in the group 274 
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which received the Montanide adjuvanted vaccine (p = 0.002) when compared to fish that 275 
received either PBS, unadjuvanted vaccine or vaccine emulsified with squalene/alum (Fig. 2 276 
A). The levels of IgM to a heterologous isolate of F. psychrophilum (AVU-1T/07, serotype 277 
Th) were also significantly elevated in both groups of fish given the vaccine emulsified with 278 
adjuvants compared to fish injected with PBS or the unadjuvanted vaccine (p = 0.010) (Fig. 2 279 
B). 280 
 281 
Figure 2. Specific antibody (IgM) levels to F. psychrophilum in vaccinated salmon 6 weeks post vaccination (A: 282 
to homologous isolate F. psychrophilum *denotes significantly different to other groups p=0.002; B: to a 283 
heterologous isolate F. psychrophilum; groups that do not share a letter are significantly different (p=0.01).  The 284 
line denotes the mean antibody level of each group, n=6, 1:64 serum dilution. 285 
 286 
3.4 SDS-PAGE and Western blot 287 
Distinct bands ranging from 10-250 kDa were evident in the SDS-PAGE profiles of the F. 288 
psychrophilum isolates used to prepare the polyvalent vaccine (and a heterologous isolate 289 
AVU-1T/07) following staining with Coomassie (Fig 3A). Banding profiles of the isolates 290 
were similar, with the exception of a slight difference in the band between 20-25kDa in the 291 
heterologous isolate.  When blots of these isolates were incubated with immune sera sampled 292 
6 wpv (pooled sera with a titre of 512 by ELISA), the strongest staining was seen with serum 293 
from fish vaccinated with the Montanide and squalene/alum vaccine preparations (Fig. 3B) 294 
reflecting the results obtained by ELISA. Bands ranging from 15 to 250 kDa were recognised 295 
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by the Montanide group, whereas the serum from fish given unadjuvanted vaccine recognised 296 
bands between 37-250 kDa with much weaker staining. This was also the case with serum 297 
from fish given vaccine emulsified with squalene/alum adjuvant, with bands recognised 298 
between 37-75 kDa. These bands also stained weakly in control fish administered PBS. 299 
 300 
          301 
 302 
Figure 3. SDS-PAGE and western blotting of F. psychrophilum isolates. (A) Whole cell lysates from a 303 
heterologous isolate and vaccine isolates Lanes: (1) molecular weight markers (2) AVU171/07, (3) AVU-1T/13, 304 
(4) AVU-2T/13, (5) AVU-3S/13) were separated by SDS-PAGE and stained with Coomassie stain. Arrows 305 
indicate high intensity bands at 10-15, 20, 37-50, 75, 100 kDa. (B) Western blot analysis of the whole cell 306 
lysates (as shown in A) with serum from vaccinated or unvaccinated (control) fish. Serum used was a pool from 307 
2 fish from each treatment group (titre 1/512, six wpv). Arrows indicate high intensity bands at 15kDa and 308 
between 37-75kDa. Molecular mass standards (kDa) are indicated.  309 
 310 
3.5 Histology 311 
Internal organs of spleen, kidney, liver, heart and digestive tract were examined histologically 312 
for signs of inflammation or adverse reactions to the vaccine/adjuvants six weeks post-313 
vaccination. No histological changes were observed in the PBS injected fish. In fish 314 
administered the unadjuvanted vaccine, inflammatory cell accumulation was observed at the 315 
injection site and around the spleen, intestine and pancreatic tissue in one of the six fish 316 
sampled (Fig. 4 A, B). Another two fish had very few inflammatory cells in normal adipose 317 
A B 
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tissue around the pancreas. Vaccine emulsified with squalene and alum induced inflammatory 318 
cell infiltration higher than the FKC group but distantly less than the groups given vaccine 319 
formulated with Montanide ISA760VG adjuvant (Table 4). Lipid droplets were observed 320 
among the inflammatory cells, which originated from the squalene component of the adjuvant 321 
(Fig. 4 C, D). All six fish vaccinated with Montanide ISA760VG adjuvant showed 322 
inflammatory cell responses (Fig. 4 E, F). Three fish had severe inflammatory cell 323 
accumulations in a wide area of injection site around pancreas, intestine, liver and spleen. In 2 324 
fish, the capsule of the spleen and liver was not obvious due to infiltrated inflammatory cells 325 
accompanied by newly produced fibrous tissue in the capsule area, and these changes may 326 
lead to adhesions of internal organs. Scoring of histological changes in the different groups is 327 
shown in Table 4. 328 
Table 4. Scoring of histological reactions to injection with PBS: Phosphate buffered saline, FKC: Group 329 
vaccinated with formalin-killed cells of F. psychrophilum; FKC & squalene/alum: group vaccinated with 330 
formalin killed cells of F. psychrophilum mixed with squalene and alum adjuvant and FKC and Montanide: 331 
group vaccinated with formalin killed cells of F. psychrophilum mixed with Montanide ISA760VG adjuvant; 332 
(n=6). 333 
Treatment  
 Group 
Injection site 
inflammation  
Injection site lipid 
droplets 
Tissue adhesion 
 
PBS - (0/6) - 0/6 
FKC 
++ (1/6) 
±  (2/6) 
- 
 
0/6 
 
FKC & 
Squalene/alum 
++ (1/6) 
+ (2/6) 
± (1/6) + 0/6 
FKC & 
Montanide 
+++ (3/6) 
+ (2/6) 
± (1/6) + 2/6 
 334 
-Absent, + Minimal, ++ Mild, +++ Moderate 335 
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 336 
Figure 4. Atlantic salmon vaccinated with F. psychrophilum formalin killed cells (FKC) (A) inflammatory cell 337 
infiltrations near outer pancreas (B) Basophilic and polymorphic inflammatory cells outer spleen (bar = 50 μm). 338 
Atlantic salmon vaccinated with formalin killed cell (FKC) of F. psychrophilum mixed with squalene and alum 339 
adjuvant. (C) Inflammatory cell infiltrations near outer spleen (D) Basophilic and polymorphic inflammatory 340 
cells outer spleen (bar = 50 μm). Atlantic salmon vaccinated with formalin killed F. psychrophilum mixed with 341 
Montanide adjuvant. (E) Inflammatory cell infiltrations in injection site near outer spleen (E) and intestine (F) 342 
were observed from all 6 fish observed (bar = 50 μm). 343 
 344 
3.6 Gene Expression (RT-qPCR) 345 
The expression of cytokine genes (IL-1β, IL-8, IL-10, IFN-γ) and cell marker genes (CD4, 346 
CD8) was examined in the head-kidney 2 dpv. There was a significant up-regulation of the 347 
cytokines IFN-γ and IL-10 in fish vaccinated with FKC alone or with FKC in combination 348 
with squalene and aluminium hydroxide adjuvant when compared to control fish injected with 349 
PBS (p < 0.01) Table 5. There were no significant differences in any of the genes examined in 350 
fish vaccinated with FKC and Montanide when compared to control fish. 351 
 352 
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Table 5. Quantitative PCR (qPCR) expression of genes in the head kidney of salmon day 2 post-353 
vaccination with the F. psychrophilum vaccines. 354 
Fold change of genes in vaccinated groups compared to controls ± SE. (n=6). Expression was compared to 355 
controls injected with PBS, and * indicates significant up-regulation relative to control (p<0.05), **(p<0.01). 356 
FKC: Group vaccinated with formalin-killed cells of F. psychrophilum; FKC & squalene/alum: group vaccinated 357 
with formalin killed cells of F. psychrophilum mixed with squalene/alum adjuvant and FKC and Montanide: 358 
group vaccinated with formalin killed cells of F. psychrophilum mixed with Montanide  ISA760VG adjuvant. 359 
 360 
 361 
4. Discussion 362 
The success of many injectable vaccines for aquaculture has been attributed to the inclusion 363 
of adjuvants [6]. Five modes of action of vaccine adjuvants have been proposed: (1) 364 
immunomodulation: the ability of many adjuvants to modify the cytokine network. (2) 365 
Presentation: the ability of an adjuvant to preserve the conformational integrity of an antigen 366 
and to present the antigen to appropriate immune effector cells. (3) CTL induction: induction 367 
of CD8+ cytotoxic T-lymphocyte (CTL) responses. (4) Targeting: the ability of an adjuvant to 368 
deliver an immunogen to immune effector cells, generally via antigen presentation cells 369 
(APCs). (5) Depot generation: generation of a short-term or long-term depot to give a 370 
Gene FKC 
    22.22**± 4.05  
6.02*    ± 2.39  
3.82      ± 0.93  
1.41     ± 0.61  
1.86      ± 0.68  
1.87    ± 0.74  
FKC & Squalene/Alum 
24.25** ± 6.22 
4.10**  ±1.84  
2.31      ±0.69 
1.21      ±0.56  
1.37      ±0.85  
1.28      ±0.57 
FKC & Montanide 
1.90 ±0.35  
0.90 ±0.54 
             1.29 ±0.31 
1.06 ±0.44  
1.61 ± 0.80  
1.13 ±0.53  
IL 10 
IFNγ 
IL 1b 
IL 8 
CD4 
CD8 
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continuous or pulsed release [28]. The use of vaccine adjuvants allows for a reduction in the 371 
number of immunisations or the amount of antigen needed for immunisation.  372 
 Adjuvants are substances which enhance the immune response to an antigen [29] and 373 
one of the most effective used in aquaculture is mineral oil [30,31]. However, the traditional 374 
oil based adjuvants, such as Montanide, can cause adverse effects [8,32,33]. Therefore, there 375 
is a need to develop adjuvants for use in injectable vaccines for salmonids, which balance the 376 
efficacy-safety profile. This study compared the efficacy and safety of a novel adjuvant for 377 
salmonid aquaculture (Squalene/aluminium hydroxide) with that of the traditional water in 378 
polymer emulsion adjuvant Montanide ISA 760VG. Alum salts have a depot effect allowing 379 
the antigen to persist and the immune system to react and facilitate uptake into antigen-380 
presenting cells (APCs)[34]. MF59, an adjuvant used for humans for over 14 years, is safe 381 
and contains a low content of squalene (4.3% w/w), a biodegradable oil naturally found in 382 
plants and animals including humans. MF59 induces low injection site reactions and is able to 383 
induce fast priming of antigen-specific CD4+ T-cell responses to induce strong and long-384 
lasting memory T- and B-cell responses [35]. 385 
 386 
The polyvalent vaccine formulated with squalene/aluminium hydroxide against F. 387 
psychrophilum in this study provided significant protection to Atlantic salmon fry when 388 
administered by intraperitoneal injection with less severe side effects observed histologically 389 
as to those observed with a traditional oil-based adjuvant. The un-adjuvanted vaccine has 390 
previously been shown to provide cross-protection to trout fry against a heterologous isolate 391 
of F. psychrophilum by immersion vaccination [14]. 392 
The vaccine formulated without adjuvant resulted in a high level of protection (RPS 393 
85.7%), second only to the group given vaccine combined with the traditional water in 394 
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polymer emulsion adjuvant Montanide ISA 760VG (RPS of 95.2%). The vaccine formulated 395 
with the novel squalene/alum adjuvant also gave good protection with an RPS of 75.2%. The 396 
group administered vaccine with Montanide had significantly higher specific antibody (IgM) 397 
levels (by ELISA and western blotting) to a homologous vaccine isolate six weeks post-398 
vaccination compared with the other vaccine groups. This finding was in agreement with 399 
previous studies whereby the inclusion of oil-based adjuvants in vaccines developed for 400 
bacterial diseases of salmonids have been shown to stimulate a strong humoral response 401 
probably due to the retention of the antigen in the oil component of the vaccine and its 402 
subsequent slow release  [7,32,36-38]. In the present study, specific antibody levels of the 403 
other vaccinated groups to this isolate were not significantly different to those of the control 404 
fish. These groups still had relatively high levels of protection perhaps due to even low levels 405 
of specific antibodies that are highly potent in conferring protection against F. psychrophilum. 406 
Future studies should include a group given adjuvant alone to further dissect the protective 407 
mechanisms behind these vaccines.  408 
Recent studies have revealed the importance of the link between induction of the innate 409 
and adaptive immune response [39]. The type and strength of the signals recognised by the 410 
innate receptors, such as PRRs and cytokines, following vaccination affect the type of 411 
adaptive immune response induced [40]. When specific antibody was measured to an isolate 412 
of F. psychrophilum (AVU-1T/07) that was not present in the vaccine (a heterologous isolate) 413 
significant antibody levels were induced in both the groups given adjuvanted vaccines 414 
compared with controls or vaccine alone. The cross reaction was also observed by western 415 
blot with the strongest staining observed in the groups vaccinated with adjuvants 416 
(Squalene/Alum; Montanide). The capacity of the adjuvanted vaccine to produce a specific 417 
humoral response to a heterologous isolate is a promising indication that the combination of 418 
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all three serotypes and genetic variants in the vaccine may provide cross protection against 419 
other strains of F. psychrophilum in Atlantic salmon. Further studies using a number of 420 
heterologous isolates for challenge and adjuvant alone groups are warranted to further 421 
determine the cross-protective capacity of the vaccine for salmon. 422 
Immune gene expression in head-kidney measured in the current study revealed a 423 
significant up-regulation of interferon gamma and interleukin-10 cytokines in all the 424 
vaccinated groups, except for those administered vaccine with Montanide. A similar pattern 425 
was observed when Atlantic salmon fry were experimentally infected with Salmonid 426 
alphavirus (SAV) with up-regulation of IFN-γ and IL-10 two to four weeks post-infection in 427 
head-kidney indicating a pro-inflammatory response [19]. IFN-γ is a type II IFN and has 428 
regulatory roles in both innate and adaptive immunity, including activating macrophages, 429 
enhancing antigen presentation and promoting the Th1 T cell responses. The involvement of 430 
IFN-γ at such an early stage post-vaccination (day two) suggests the stimulation of antigen 431 
presenting cells such as macrophages. IFN-γ is a powerful immunopotentiator and therefore 432 
needs to be under tight control (IL-10) as shown in studies of higher vertebrates [41]. Similar 433 
responses were seen in Atlantic salmon given oil-adjuvanted vaccines i.p. for Aeromonas 434 
salmonicida and infectious pancreatic necrosis virus, where gene expression profiling was 435 
used to investigate the T cell mediated immune response in spleen and head kidney from 1 to 436 
28 dpv [18]. Expression of IFN-γ and IL-10 increased 2 dpv in spleen and head kidney in the 437 
group vaccinated with the bacterial vaccine (A. salmonicida), suggesting the importance of 438 
these cytokines and their interaction following vaccine delivery. In contrast to these studies 439 
the group given the F. psychrophilum vaccine formulated with Montanide adjuvant in the 440 
present study had no significant up-regulation of gene expression 2 dpv. Gene expression may 441 
have been delayed in this group due to the retention of the antigen compared with the other 442 
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groups as indicated by the inflammatory response observed histologically six wpv in this 443 
group.  444 
Moderate inflammatory reactions were observed histologically in the fish 445 
administered the vaccine in conjunction with Montanide, whereas fish administered vaccine 446 
without adjuvant or the novel squalene/alum adjuvant had less inflammatory cell 447 
accumulations at the injection site as was observed when squalene based vaccines were used 448 
in humans[35]. This could be an indication of the differing mode of action of the adjuvants as 449 
the squalene/alum adjuvant (oil in water adjuvant) may have been more readily metabolised 450 
by the fish resulting in less chronic inflammation. 451 
Squalene/alum adjuvants have seldom been incorporated into vaccines for 452 
aquaculture. Where it has been used the results have been impressive. Squalene/alum adjuvant 453 
was used in a vaccine for prevention of F. psychrophilum in Ayu (Plecoglossus altivelis) 454 
where it induced specific antibody titres and protection similar to that achieved with 455 
Montanide [42]. In addition it has been used to produce an effective vaccine with minimal 456 
side effects against VHS in Olive flounder [11]. The inclusion of this adjuvant in the present 457 
study produced significant protection in salmon against RTFS with less severe side effects 458 
observed histologically as to those observed with a traditional oil-based adjuvant and as such 459 
may hold promise for developing future vaccines for aquaculture, although length of 460 
protection still needs to be established. Future trials incorporating this adjuvant should 461 
therefore include long term efficacy studies and studies on protection in rainbow trout. 462 
Alternative methods of vaccine administration should also be tested (e.g. immersion 463 
vaccination) to enable vaccination of Atlantic salmon fry.  464 
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 581 
 582 
Figure S1 a. Nested PCR for detection of F. psychrophilum in DNA extracted from eggs. 1% agarose gel 583 
showing second round PCR products. Lane 1: (M) Ladder, Lane 2-6: Trout egg DNA, Lane 7-10: positive F. 584 
psychrophilum DNA, Lane 11: negative water.  585 
 586 
Figure S1b. Nested PCR for detection of F. psychrophilum in colonies recovered from moribund/mortalities 587 
post-challenge. 1% agarose gel showing second round PCR products. M: Ladder, Lane1-16: bacterial DNA 588 
recovered from fish, (-) negative control, (+): positive control. 589 
 590 
 591 
Table S1. Survival analysis of different treatment groups showing results for individual tanks. Treatment 1: 592 
Control tank 1; 2: Control tank 2; 3: FKC tank 1; 4: FKC tank 2; 5: FKC & squalene tank 1; 6: FKC & Squalene 593 
tank 2; 7: FKC & Montanide tank 1; 8: FKC & Montanide tank 2. 594 
 595 
Overall Comparisonsa 
Wilcoxon 
(Gehan) Statistic df Sig. 
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37.930 7 .000 
a. Comparisons are exact. 
 596 
 597 
Pairwise Comparisonsa 
(I) treatment (J) treatment 
Wilcoxon 
(Gehan) Statistic df Sig. 
1 2 2.770 1 .096 
3 8.339 1 .004 
4 1.493 1 .222 
5 3.973 1 .046 
6 2.633 1 .105 
7 8.339 1 .004 
8 5.299 1 .021 
2 1 2.770 1 .096 
3 16.143 1 .000 
4 7.067 1 .008 
5 11.654 1 .001 
6 8.468 1 .004 
7 16.143 1 .000 
8 12.604 1 .000 
3 1 8.339 1 .004 
2 16.143 1 .000 
4 3.212 1 .073 
5 2.069 1 .150 
6 2.219 1 .136 
8 1.000 1 .317 
4 1 1.493 1 .222 
2 7.067 1 .008 
3 3.212 1 .073 
5 .450 1 .502 
6 .158 1 .691 
7 3.212 1 .073 
8 1.183 1 .277 
5 1 3.973 1 .046 
2 11.654 1 .001 
3 2.069 1 .150 
4 .450 1 .502 
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6 .021 1 .884 
7 2.069 1 .150 
8 .268 1 .605 
6 1 2.633 1 .105 
2 8.468 1 .004 
3 2.219 1 .136 
4 .158 1 .691 
5 .021 1 .884 
7 2.219 1 .136 
8 .436 1 .509 
7 1 8.339 1 .004 
2 16.143 1 .000 
4 3.212 1 .073 
5 2.069 1 .150 
6 2.219 1 .136 
8 1.000 1 .317 
8 1 5.299 1 .021 
2 12.604 1 .000 
3 1.000 1 .317 
4 1.183 1 .277 
5 .268 1 .605 
6 .436 1 .509 
7 1.000 1 .317 
a. Comparisons are exact. 
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